Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Lakehouse Global Growth Fund Nick, Erwin and Donny | “Veeva Systems, our second-largest contributor, was a position we established in March during the indiscriminate sell-off across software. The company is the dominant, mission-critical software provider to the life sciences industry, with a base of more than 1,500 customers including 19 of the top 20 global pharmaceutical companies using at least one Veeva product. Put simply, as pharmaceutical companies bring a drug from clinical trial through regulatory approval to commercial launch, nearly every step of that process happens on a Veeva product. This includes tracking trial documents, managing regulatory submissions, running quality and safety systems, and supporting sales representatives as they engage with doctors. Once embedded across these workflows, Veeva is exceptionally difficult to displace. Decades of industry-specific data and domain specialisation give Veeva a durable moat, and we believe they are best placed to leverage AI rather than be disrupted by it. The reason is structural: AI in a regulated industry is only as useful as the governed data foundation it sits on. Life sciences companies cannot responsibly deploy AI agents on ungoverned, unvalidated data given the severity of compliance and audit requirements in the industry. Veeva has spent over a decade building exactly that foundation, comprising built-in audit trails and compliance workflows designed to streamline the path to FDA approval. This gives Veeva's agentic products a credibility advantage in a highly regulated, risk-averse industry where trust is earned slowly and lost quickly. And Veeva is not standing still. The first Veeva AI agents went live in December and a new agentic platform, Falcon, is targeting availability later this year. In our view, the winner of the AI race in life sciences will be determined less by who deploys agents first and more by the richness and quality of the industry-specific data those agents will ultimately rely on, a race we think Veeva is well placed to win.” | BULL | Q2 2026 Jul 29, 2026 | View Pitch |
Vulcan Value Partners - All Cap C.T. Fitzpatrick | “Veeva is the dominant vertical market software system of record for the life sciences industry. Their customers rely on and trust Veeva to help them run their entire business. Everything from the development, regulatory approval, and manufacturing of drugs to the selling and marketing of drugs runs on Veeva's platform. Veeva grew revenue and EBIT 16% and 24%, respectively in 2025 and it is off to a strong start in 2026. Despite these strong results, the stock is down close to 20% year to date through the end of June in sympathy with the rest of the application software sector. We believe Veeva is one of the most resilient software businesses on our MVP list due to the mission critical nature of its platform and its focus on the highly regulated life sciences industry. AI is a complement to Veeva's software, not a substitute. Veeva's customers want to and will adopt AI across their businesses, but the regulatory and compliance demands of these customers are immense and the need for 100% accuracy is paramount. Mistakes by these companies often lead to large fines, failed clinical trials, drugs being pulled from the market, and adverse patient outcomes. Therefore, the quality of the data, the systems of record, the software that runs these companies' workflows and business processes are just as important today as they have ever been. Veeva continues to innovate, embedding industry specific, compliant AI into its deeply integrated core applications. We see AI as just another growth driver for Veeva and believe the company will lean on its core strengths including its proprietary data, domain expertise, integrated platform, and trusted, embedded customer relationships to win. We have long admired Veeva's customer centricity, track record of innovation, and focus on long term value creation. The company has $7 billion of net cash on its balance sheet, produces significant free cash flow, and is buying back shares at a large discount to our estimate of intrinsic value. We are thrilled with the opportunity to buy such a great business at such a great price.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Fundsmith Equity Fund Terry Smith | “Veeva provides specialised cloud-based software designed specifically for the pharmaceutical and life sciences industries. Its software tracks the entire lifecycle of a drug from clinical trials throu” | NEUTRAL | Q2 2026 Jul 8, 2026 | View Pitch |
VVP Q2 Letter 06.30.26 Portfolio Manager | “Veeva Systems has traded down alongside the broader application software space despite showing outstanding financial performance and maintaining a massive cash cushion. Its vertical-specific software is essential for clinical trials and regulatory compliance in life sciences, areas where absolute data accuracy prevents AI from displacing its core products.” | BULL | Q2 2026 Jun 30, 2026 | View Pitch |
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Veeva Systems has a leading customer relationship management platform for pharmaceutical sales and marketing organizations and has extended its franchise into pharmaceutical R&D through additional software modules. Despite reporting solid results with recurring revenue up 18%, driven by adoption of its R&D and commercial cloud solutions, we exited the position due to rising competitive and AI-driven risks. BSD Analysis: Veeva owns the operating system of regulated life sciences, where compliance risk creates brutal switching costs. CRM is just the entry point; clinical, quality, and regulatory modules drive expansion. Biotech funding slowdowns hurt growth optics, not customer dependence. Regulators implicitly entrench incumbents by expecting standardized workflows. Pricing power exists because failure is not an option. Investors compare Veeva to generic SaaS and miss the moat. As pipelines restart, growth reaccelerates quietly. Margins reflect mission-critical software economics. This is regulated SaaS that compounds on its own clock.” | BEAR | Q4 2025 Jan 15, 2026 | View Pitch |
TimesSquare Capital Management U.S. FOCUS Growth Equity strategy Portfolio Manager | “Veeva Systems Inc. provides industry cloud solutions to the global life sciences industry. The company delivered solid fiscal third-quarter results and issued guidance above the Street. Veeva management reiterated confidence in achieving its 2030 financial targets, maintaining that the current focus on competitive dynamics with Salesforce.com in the customer relationship management (CRM) market (20% of Veeva's total revenues) does not undermine its long-term trajectory. Despite these positives, the stock sold off by -25% on competitive concerns in the CRM market as Veeva projected lower Vault CRM customer versus its initial expectations. BSD Analysis: Veeva owns the operating system of regulated life sciences, where compliance risk makes switching software dangerous. CRM is just the entry point; clinical, quality, and regulatory modules drive durable expansion. Biotech funding slowdowns hurt growth optics, not customer dependence. Regulatory standards effectively entrench incumbents like Veeva. Pricing power exists because failure is not an option. Investors compare Veeva to generic SaaS and miss the moat. As pipelines restart, growth reaccelerates naturally. This is regulated SaaS compounding on its own clock.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Ithaka US Growth Strategy Scott O'Gorman, Andy Colyer, Daniel White | “Veeva Systems has grown into the leading SaaS provider of cloud solutions for the life sciences industry, offering software for CRM, content, data, and regulatory compliance. During the quarter, the stock underperformed following its earnings announcement, despite beating revenue and earnings expectations. Management stated it is now targeting 14 of the top 20 global pharmaceutical companies for its new Vault CRM product, down from prior indications of 16. The market interpreted this reduction as evidence that competitors such as Salesforce's Life Sciences Cloud are gaining traction. This perception drove the stock lower during the quarter. BSD Analysis: Veeva owns regulated life sciences software the same way Bloomberg owns financial data — through necessity, not choice. Its CRM, quality, and regulatory platforms are embedded deep inside pharma workflows where failure is not an option. Switching costs are enormous because compliance risk dwarfs licensing fees. Growth has slowed as large pharma matures, but expansion into adjacent regulated industries adds optionality. The company's independence from big cloud vendors remains a strategic advantage. Margins and cash flow are elite because Veeva doesn't overspend to grow. This business trades like SaaS but behaves like infrastructure. Boring to watch, brutal to compete with. Exactly what you want.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Brown Advisory Large-Cap Growth Strategy Brown Advisory LLC | “Veeva Systems (VEEV) traded lower during the quarter despite posting strong results and raising full-year guidance. The company delivered solid revenue growth and continued to demonstrate strong profitability, reinforcing its long-term financial targets. Investor concerns centered on increased competitive pressure in CRM from Salesforce, which weighed on sentiment despite Veeva's progress in expanding its product portfolio and deepening customer relationships. We believe Veeva remains well positioned as a leader in life sciences software, supported by durable growth drivers. BSD Analysis: Veeva owns regulated life sciences software the way Bloomberg owns financial data — through necessity, not preference. Its CRM, quality, and regulatory platforms are embedded deep inside pharma workflows. Switching costs are enormous because compliance risk dwarfs licensing cost. Growth has slowed as large pharma matures, but wallet share continues to expand. Independence from hyperscalers remains a strategic advantage. Margins are elite because Veeva doesn't overspend to win deals. AI improves efficiency without undermining the moat. This is not flashy SaaS. It's regulated software infrastructure with brutal durability.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
“Veeva declined ~25% despite delivering good results and strong guidance as management disclosed that 14 of the top 20 customers will transition to the new CRM platform (vs. 16 expected). The revenue impact will be small and more than offset by new module expansions and growth in the R&D segment. BSD Analysis: Veeva owns the operating system of regulated life sciences, where compliance risk makes switching software dangerous. CRM is only the entry point; clinical, quality, and regulatory modules drive durable expansion. Biotech funding slowdowns hurt growth optics, not customer dependence. Regulators implicitly entrench incumbents by expecting standardized workflows. Pricing power exists because failure is not an option. Investors compare Veeva to generic SaaS and miss the moat. As pipelines restart, growth reaccelerates naturally. This is regulated software compounding on its own clock.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch | |
Conestoga Mid Cap Composite Conestoga Capital Advisors, LLC | “Veeva Systems, Inc. (VEEV) underperformed during the quarter despite maintaining a dominant market position and raising full-year guidance. Shares declined as investors rotated away from higher-valuation software names and expressed caution over the timing of large enterprise deal closures. Near-term growth visibility was questioned despite strong fundamentals. We continue to view VEEV as strategically critical to life sciences customers, with a broadening product runway. Short-term sentiment rather than fundamentals drove weakness. BSD Analysis: Veeva owns the operating system of regulated life sciences, where compliance risk creates brutal switching costs. CRM is just the entry point; quality, clinical, and regulatory modules drive expansion. Growth slowed as biotech funding tightened, testing investor patience. But customers don't abandon systems that regulators expect to see. Pricing power exists because failure is not an option. Margins reflect software economics layered onto mission-critical workflows. Investors treat Veeva like generic SaaS, which misses the moat. As pipelines restart, growth reaccelerates quietly. This is regulated software compounding at its own pace.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Carillon Eagle Mid Cap Growth Fund Eric Mintz, Christopher Sassouni, David Cavanaugh | “Veeva Systems provides cloud-based software solutions for the life sciences industry. The stock struggled after third-quarter results, as management acknowledged competitive losses despite otherwise solid performance. The company has introduced a suite of AI products aimed at mitigating these losses and sees opportunities to win back customers given its broad product portfolio. With its deep expertise in life sciences and a comprehensive platform, we believe Veeva remains well positioned to continue capturing market share. BSD Analysis: Veeva's moat is vertical dominance in life sciences workflows where compliance and validation create massive switching friction. Pricing power is earned through necessity, not seat counts. Growth is steady and durable, though capped by industry size. Transitioning away from Salesforce dependency adds execution risk but increases control. Competition is limited by regulatory burden and domain expertise. Margins remain strong due to subscription economics. The bull case is deeper platform penetration across R&D and commercial. The bear case is slower growth as saturation approaches. Veeva compounds by owning regulated workflows—and staying focused.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Bell Global Emerging Companies Fund Ned Bell, Joel Connell, Matt Saddington | “Other laggards included Veeva Systems (Health Care). The stock detracted from performance during December amid sector-level weakness. No company-specific deterioration was highlighted. Veeva continues to serve as critical infrastructure for life sciences customers with high switching costs. Performance reflects valuation and sentiment pressures rather than a change in fundamentals. BSD Analysis: Veeva owns regulated life sciences software in a way that makes competition mostly academic. Its CRM, quality, and regulatory platforms are embedded in pharma workflows where failure isn't tolerated. Switching costs are enormous because compliance risk dwarfs license fees. Growth has slowed as large pharma matures, but wallet share continues to expand. Independence from hyperscalers remains a strategic advantage. Margins are elite because Veeva doesn't overspend to win deals. AI enhances productivity but doesn't threaten the core. This is not flashy SaaS. It's regulated software infrastructure that compounds quietly.” | BULL | Q4 2025 Nov 30, 2025 | View Pitch |
Conestoga Mid Cap Composite Conestoga Capital Advisors, LLC | “Veeva Systems, Inc. (VEEV) VEEV is a vertical SaaS company for the life sciences industry with a wide range of integrated cloud-based software applications and services. VEEV reported a strong start to their fiscal year, materially outperforming expectations across the board. The company added 28 new Vault CRM customers during the quarter, marking over 80 customers live vs. only a handful a year ago. Additionally, VEEV now expects about 200 Vault CRM customers by next year. BSD Analysis: Veeva remains a category-defining vertical SaaS leader with deep entrenchment across pharma commercial and R&D workflows. Rapid adoption of Vault CRM underscores customer willingness to migrate away from legacy platforms and deepen standardization on Veeva's stack. The business model is highly recurring and capital-light, supporting strong free cash flow conversion and a robust net cash position. Over time, incremental modules and data products can lift ARPU and expand the addressable market. While the stock trades at a premium EV/sales and EV/EBIT, its predictable growth, high returns on capital, and near-monopoly positioning in key niches justify a structurally higher multiple.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
